DEZ 001

Drug Profile

DEZ 001

Alternative Names: DEZ-001; TA-8995

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Amgen; Mitsubishi Tanabe Pharma Corporation; Xention
  • Class Antihyperlipidaemics
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias

Most Recent Events

  • 17 Sep 2015 Dezima Pharma, Mitsubishi Tanabe Pharma and Amgen sign a patent, know-how transfer and licensing agreement for DEZ 001
  • 01 Aug 2015 Phase-I clinical trials in Dyslipidaemias (In volunteers) in United Kingdom (PO)
  • 08 Apr 2015 Xention plans a phase I trial in Healthy male volunteers in United Kingdom (NCT02408055)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top